Larimar Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing treatments for patients with complex rare diseases using its novel cell penetrating peptide (CPP) technology platform. This platform enables therapeutic molecules to cross cell membranes to reach intracellular targets, which is essential for addressing diseases where the therapeutic agent must access organelles such as mitochondria. The company's lead product candidate, nomlabofusp, is a subcutaneously administered recombinant fusion protein designed to deliver frataxin (FXN) to mitochondria for treating Friedreich's ataxia (FA), a rare, progressive, and fatal genetic disorder characterized by deficient FXN production due to a hereditary mutation. With no current therapies targeting the underlying FXN deficiency in FA, nomlabofusp represents the first potential therapy designed to systemically increase FXN levels in patients with FA. Beyond FA, Larimar intends to apply its CPP platform to additional rare orphan diseases involving intracellular protein deficiencies or dysfunction, seeking to create a versatile treatment modality for multiple high unmet medical need indications.

As a clinical-stage company with no approved products on the market, Larimar Therapeutics, Inc. does not currently generate revenue from therapeutic sales. The company finances its research, development, and operational activities primarily through equity financings and related capital-raising activities. Notably, the February 2026 public offering of common stock yielded net proceeds of $107.6 million, which, combined with the company's cash position of $136.9 million as of December 31, 2025, is expected to fund operations into the second quarter of 2027. This financial runway supports ongoing clinical advancement of nomlabofusp, refinement of the CPP technology platform, and general corporate activities necessary to achieve key regulatory milestones.

Larimar Therapeutics, Inc. operates in the competitive rare disease therapeutics market, contending with approved therapies and numerous pipeline candidates. For Friedreich's ataxia specifically, the company competes against Biogen's SKYCLARYS (omaveloxolone), which received FDA approval in February 2023 and European Commission approval in February 2024 for treating FA in patients aged 16 and older. Additional competitors advancing FA treatments include Design Therapeutics, Lexeo Therapeutics, the Neurocrine Biosciences/Voyager Therapeutics collaboration, Solid Biosciences, and PTC Therapeutics, which encountered an FDA complete response letter in August 2025 requiring further study for potential resubmission. While many competitors possess advantages in greater financial resources, extended operational histories, and superior technical manufacturing capabilities, Larimar differentiates itself through its proprietary CPP technology enabling targeted intracellular protein delivery, its scientific focus on correcting the root cause of FA rather than merely managing symptoms, and its robust intellectual property portfolio protecting nomlabofusp composition, use, and innovations related to the platform.

Upon achieving regulatory approval for nomlabofusp, Larimar Therapeutics, Inc. will serve patients diagnosed with Friedreich's ataxia, a condition affecting approximately 20,000 individuals globally according to epidemiological data, with approximately 5,000 residing in the United States and the majority of remaining patients located in Europe. The company anticipates engaging healthcare providers such as neurologists, specialized neuromuscular clinics, and multidisciplinary treatment centers as key customers, alongside healthcare systems managing patient access and reimbursement. Patients themselves will access nomlabofusp through prescription pathways, potentially involving specialty distribution channels. Furthermore, Larimar aims to expand its therapeutic applications using the CPP technology platform to address additional rare diseases involving intracellular protein deficiencies, thereby broadening its future customer base to include patients with conditions beyond Friedreich's ataxia as its pipeline develops.